Although there were no new Initial Public Offerings last week, two IPOs have announced plans to enter public markets this week, daring to brave the volatile market that has pretty much put IPOs on hold in March. The expected offerings include a Chinese hologram company and a biotech, both showing promising signs of profitability.

The Chinese holographic company WiMi Hologram Cloud is planning to raise $33 million at a $385 million market cap. The company issued the terms of its IPO by offering 5 million shares at an estimated price range of $5.50-$7.50 each. WiMi Hologram Cloud is a leading player in the Chinese holographic augmented reality business, which is an estimated $500 million market. The company's IPO is underwritten by the investment firm The Benchmark Company and has yet to disclose the date of its debut.

The New York City-based oncology biotech Zentalis Pharmaceuticals has set the terms for its IPO on Monday. The Phase 1/2 biotech developing novel small molecule therapies for various cancers plans to raise $130 million at a $580 market cap. The company plans to list on the Nasdaq and is offering 7.7 million shares set to price between $16-$18 each. The company plans to list about 7.6 million share at $16-$18 each. Investment firms Morgan Stanley (MS  ) and Jefferies Financial Group (JEF  ) are underwriters for the IPO. In its prospectus, Zentalis noted that the COVID-19 outbreak has had an impact on clinical trails, as normal company functions have been delayed.